Researchers across the UAE who run tesamorelin protocols ask the same question first: "What is this GHRH analog going to do to my fasting glucose?" It is the single most common concern in our Dubai inbox, and a fair one — the original Stanley 2014 NEJM-era data and the Falutz 2007 trial both reported a small but real disturbance to glycaemic markers in the first weeks of dosing. If you are buying tesamorelin in Dubai, Abu Dhabi or Sharjah and you want a protocol that turns this uncertainty into measurable data, this is the continuous-glucose-monitor (CGM) blueprint Gulf research desks have settled on. REVIVE LAB UAE keeps tesamorelin 5 mg and 10 mg vials in stock for same day delivery to Dubai Marina, JBR, Business Bay and DIFC, with 24h delivery to the northern emirates — so you can pair your CGM start date with the vial arrival. This is the peptides UAE workflow that has replaced guesswork with logged data.
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It pulses the pituitary to release endogenous growth hormone (GH), which in turn lifts IGF-1 and mobilizes triglycerides from visceral adipose tissue (VAT). The trade-off — well-mapped in the literature — is that GH is a counter-regulatory hormone. It opposes insulin at the hepatocyte and adipocyte level, transiently nudging hepatic glucose output upward and reducing peripheral glucose uptake.
That mechanism is exactly why the Stanley 2014 visceral fat trial in HIV-associated lipodystrophy is the most-cited tesamorelin reference in the UAE peptides community. Across 26 weeks of 2 mg daily tesamorelin in 50 adults, VAT fell by approximately 15–18%, but fasting glucose rose by a mean of roughly 5 mg/dL and HbA1c crept from 5.2% to 5.4% by week 13 before flattening. The Falutz 2007 multicenter trial (n=412) reported the same pattern: a transient first-quarter glycaemic shift that did not progress to overt impaired fasting glucose in most participants. Stanley 2019 follow-up work emphasised that the GH-induced insulin resistance was dose-dependent and largely reversed once the visceral fat loss "caught up" with the GH signal, with adiponectin recovering by the six-month mark.
Translation for a Dubai researcher: the GH-driven glucose bump is real, it is small, it is front-loaded, and it tends to self-resolve as VAT shrinks and adiponectin recovers. The only way to confirm that on your own data — rather than trust the cohort means — is to wear a CGM. That is why the UAE protocol below has become the default among independent Gulf research desks.
The protocol below is the consolidated approach used by independent research groups in Dubai, Abu Dhabi and Sharjah pairing tesamorelin 5 mg or 10 mg vials with a 14-day Freestyle Libre 3 or Dexcom G7 sensor. It is not medical advice; it is the data-capture framework readers have asked us to publish.
| Week | Tesamorelin dose | CGM action | Primary metric logged |
|---|---|---|---|
| −2 to 0 (baseline) | None — washout | Wear sensor 14 days | Mean glucose, time-in-range 70–140 mg/dL |
| 1–3 (induction) | 1 mg SC nightly (titrate) | No sensor | Weight, waist circumference |
| 4 (mid-check) | 2 mg SC nightly | Wear sensor 14 days | Mean glucose delta vs baseline, post-meal AUC |
| 5–11 (steady state) | 2 mg SC nightly | No sensor; weekly fasting fingerstick | Fasting glucose drift |
| 12 (endpoint) | 2 mg SC nightly | Wear sensor 14 days | Time-in-range recovery, mean glucose normalisation |
| 13–26 (extension) | 2 mg or pulse 5-on-2-off | Optional sensor at week 24 | HbA1c venous draw |
By week 4 the typical pattern is a mean glucose increase of 4–9 mg/dL and a time-in-range reduction of 3–6 percentage points. Post-prandial peaks after a standard 75 g carbohydrate meal usually rise 10–18 mg/dL and take 20–30 minutes longer to return to baseline. By the week 12 sweep, almost all of those metrics drift back toward baseline as VAT falls. If they do not — if your week 12 mean glucose remains elevated — that is the signal Stanley 2019 flagged: dose-down, lengthen the off-cycle, or pause.
Because the GH pulse from a night-time tesamorelin injection lifts hepatic glucose output through the early-morning hours, UAE researchers commonly time injections so the pulse aligns with an existing overnight fasted window. The result on the CGM trace is a cleaner morning curve and a more interpretable post-breakfast spike. This pairing alone — rather than any change to dose — is the single most common reason a week-4 CGM bump looks "worse" than it actually is.
REVIVE LAB UAE dispatches tesamorelin from a temperature-controlled Dubai facility. Same-day delivery is the default for Dubai Marina, JBR, Jumeirah, Business Bay, DIFC, JVC, Palm Jumeirah, Downtown, Emirates Hills and Arabian Ranches when your order is placed before 14:00 GST. Orders to Abu Dhabi, Sharjah and Ajman ship the same evening and arrive within 24 hours. The northern emirates (RAK, Fujairah, UAQ) and Al Ain are reached inside 24–48 hours via our cold-chain courier. Every vial is shipped in plain, unbranded packaging with no peptide name on the waybill — the courier sees only the consignee name.
| Emirate | Delivery window | Cash on delivery |
|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Palm, Downtown) | Same day (order by 14:00) | Yes |
| Abu Dhabi (Corniche, Reem, Saadiyat, Yas) | Next morning, 24h | Yes |
| Sharjah | 24 hours | Yes |
| Ajman | 24 hours | Yes |
| Ras Al Khaimah (RAK) | 24–48 hours | Yes |
| Fujairah | 24–48 hours | Yes |
| Umm Al Quwain (UAQ) | 24–48 hours | Yes |
| Al Ain | 24–48 hours | Yes |
If you want a same-day drop in Dubai Marina, JBR, Jumeirah, Business Bay, JVC, DIFC, Palm Jumeirah, Downtown, Emirates Hills or Arabian Ranches, place your tesamorelin order before 14:00 GST and your courier will reach you the same evening with a cold-pack vial.
REVIVE LAB UAE is a UAE-based peptides supplier, not a re-shipper. We hold tesamorelin 5 mg and 10 mg vials in physical Dubai inventory, lot-tested by HPLC at >99% purity, and dispatch via a dedicated cold-chain courier so the cold cycle is never broken between freezer and front door. Every shipment leaves in discreet, unbranded packaging with no peptide name printed on the waybill, and we accept cash on delivery across all seven emirates. Same-day dispatch from Dubai is the default for orders placed before 14:00 GST — which is why Gulf researchers running tight CGM protocols rely on us when sensor day-1 has to line up with vial arrival. Explore the full REVIVE LAB UAE peptides catalogue for the rest of the in-stock library.
REVIVE LAB UAE ships HPLC-tested tesamorelin 5 mg and 10 mg vials from a Dubai facility, with same-day dispatch in Dubai and Abu Dhabi and 24–48 hour delivery to Sharjah, Ajman, RAK, Fujairah, UAQ and Al Ain. Cash on delivery and discreet anonymous packaging are available across every emirate. Place your order before 14:00 GST for same-evening arrival inside Dubai. This is the fastest peptides UAE channel for tesamorelin.
In Stanley 2014 and Falutz 2007, tesamorelin produced a small early rise in fasting glucose (typically 3–8 mg/dL) and a marginal HbA1c bump that flattened or reversed by week 26 in most participants. The Stanley 2019 follow-up emphasised that the effect is dose-dependent and largely reflects the GH-driven counter-regulatory pulse, not a true progression toward impaired glucose tolerance. UAE researchers running the CGM protocol described above almost always see metrics drift back toward baseline as visceral fat falls.
The two dominant choices on Gulf research desks are the Freestyle Libre 3 (14-day sensor, no fingerstick calibration) and the Dexcom G7 (10-day sensor, tighter accuracy on the post-prandial rise). Both are widely available in Dubai pharmacies. The protocol above is sensor-agnostic — what matters is that you capture a baseline week, a mid-cycle week 4 window, and a week 12 endpoint window so you can compare three apples-to-apples 14-day traces.